Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019162 | 0.87 | CA12 (0.53) | ALDH1A1CYP2C9CA1CA2CA9 | |
| SCHEMBL20155326 | 0.87 | ALDH1A1 (0.59) | ALDH1A1VCAM1CYP2C9SMN1; SMN2CA1 | |
| SCHEMBL16492321 | 0.81 | ALDH1A1 (0.65) | ALDH1A1VCAM1CYP2C9SMN1; SMN2CA1 | |
| SCHEMBL3017872 | 0.81 | LMNA (0.49) | ALDH1A1VCAM1SMN1; SMN2CA1CA2 | |
| SCHEMBL23092777 | 0.80 | CA1 (0.56) | ALDH1A1VCAM1CYP2C9SMN1; SMN2CA1 | |
| SCHEMBL29715364 | 0.80 | CA1 (0.56) | ALDH1A1VCAM1CYP2C9SMN1; SMN2CA1 | |
| SCHEMBL30602398 | 0.79 | GAA (0.42) | ALDH1A1CYP2C9CA1CA2CA9 | |
| SCHEMBL2112292 | 0.79 | GAA (0.42) | ALDH1A1CYP2C9CA1CA2CA9 | |
| SCHEMBL3025163 | 0.78 | CNR2 (0.57) | ALDH1A1CYP2C9SMN1; SMN2CA1CA2 | |
| SCHEMBL120400 | 0.78 | PKM (0.61) | ALDH1A1VCAM1SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | ALDH1A1 946/4885VCAM1 3276/4885CYP2C9 1287/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | ALDH1A1 1586/4885VCAM1 2503/4885CYP2C9 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.